Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 116.00 | |
2 mg | In stock | $ 169.00 | |
5 mg | In stock | $ 289.00 | |
10 mg | In stock | $ 478.00 | |
25 mg | In stock | $ 789.00 | |
50 mg | In stock | $ 1,080.00 | |
100 mg | In stock | $ 1,480.00 | |
500 mg | In stock | $ 2,970.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 297.00 |
Description | PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model. |
In vitro | PD-1/PD-L1-IN-9 (46.9-1500 nM; pretreated for 2 h) dose-dependently significantly activates the antitumor immunity of PBMCs to MDB-MB 231 cells, EC50 = ∼100 nM[1]. |
In vivo | PD-1/PD-L1-IN-9 (40-80 mg/kg; p.o. once a day for 2 weeks) inhibits tumor growth in a dose-dependent manner and does not cause any body weight loss or mortality of mice. PD-1/PD-L1-IN-9 (3 mg/kg; a single i.v.) exhibits half-life (t1/2=4.2 h), plasma clearance (Cl=11.5 L/h/kg) and Cmax (1233 ng/mL) in rats. PD-1/PD-L1-IN-9 (25 mg/kg; a single p.o.) exhibits moderate oral bioavailability (F=22 %), half-life (t1/2=6.4 h) and Cmax (192 ng/mL) in rats[1]. |
Molecular Weight | 348.44 |
Formula | C22H24N2O2 |
CAS No. | 2628506-54-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (258.3 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PD-1/PD-L1-IN-9 2628506-54-5 Apoptosis Cell Cycle/Checkpoint Immunology/Inflammation PD-1/PD-L1 PD1/PDL1IN9 PD 1/PD L1 IN 9 inhibitor inhibit